Bukwang Pharmaceutical announced on the 24th that it has launched 'Bukwang Brifil 10·25·50·100mg' (active ingredient: brivaracetam), a treatment for epilepsy.
Bukwang Brifil received product approval from the Ministry of Food and Drug Safety in September last year. It is a third-generation epilepsy treatment used as adjunctive therapy for patients with partial-onset seizures. Brivaracetam, the main component of Bukwang Brifil tablets, selectively binds to synaptic vesicle protein 2A (SV2A) and suppresses seizures by regulating neurotransmitter release.
Bukwang Brifil features faster absorption and superior tolerability compared to existing treatments. Additionally, various dosage options enable customized treatment tailored to individual patient conditions.
A Bukwang Pharmaceutical official stated, "Bukwang Brifil is a product that can provide a new treatment option for epilepsy patients." The official added, "Based on its rapid onset of action and excellent safety profile, it is expected to contribute to improving the quality of life for epilepsy patients."
The official continued, "With the newly secured combination option with our currently marketed Orfil family (extended-release tablets, syrup, and injection), this will provide practical assistance to epilepsy specialists in patient treatment." The official further noted, "With the launch of Bukwang Brifil, we plan to further strengthen our position in the central nervous system (CNS) area and continue investing in the development of treatments for neurological disorders including epilepsy."